Latest revision as of 17:13, 17 July 2024

Back to Top

Page editor		Section editor
	Laura S. Graham, MD University of Colorado Anschutz Medical Campus Aurora, CO, USA LinkedIn		Ali Raza Khaki, MD Stanford University Palo Alto, CA, USA LinkedIn

7 regimens on this page 8 variants on this page

Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

NCCN

NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Prostate Cancer.

Metastatic castration-resistant

Abiraterone monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Fizazi et al. 2023 (TRITON3)	2017-02-08 to 2022-02-02	Phase 3 (C)	Rucaparib	Inferior PFSi (primary endpoint)
de Bono et al. 2020 (PROfound)	2017-04 to 2018-11	Phase 3 (C)	Olaparib	Seems to have inferior OS
Chi et al. 2023 (MAGNITUDE)	2019-05 to 2021-03	Phase 3 (C)	Abiraterone & Niraparib	Inferior rPFS

Endocrine therapy

Abiraterone (Zytiga) 1000 mg PO once per day on days 1 to 28

Supportive therapy

Prednisone (Sterapred) 5 mg PO twice per day or 10 mg PO once per day on days 1 to 28

28-day cycles

References

PROfound: de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. link to original article dosing details in manuscript have been reviewed by our editors link to supplementary appendix PubMed NCT02987543
1. Update: Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10;383(24):2345-2357. Epub 2020 Sep 20. link to original article PubMed
2. HRQoL analysis: Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Mar;23(3):393-405. Epub 2022 Feb 11. Erratum in: Lancet Oncol. 2022 Apr;23(4):e161. link to original article PubMed
TRITON3: Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. link to original article link to PMC article dosing details in supplement have been reviewed by our editors PubMed NCT02975934
MAGNITUDE: Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. Epub 2023 Mar 23. link to original article link to PMC article PubMed NCT03748641
1. Update: Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, Castro E, Roubaud G, Pereira de Santana Gomes AJ, Small EJ, Rathkopf DE, Gurney H, Jung W, Mason GE, Dibaj S, Wu D, Diorio B, Urtishak K, Del Corral A, Francis P, Kim W, Efstathiou E. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023 Sep;34(9):772-782. Epub 2023 Jul 1. link to original article link to PMC article PubMed

Abiraterone & Niraparib

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Chi et al. 2023 (MAGNITUDE)	2019-05 to 2021-03	Phase 3 (E-RT-esc)	Abiraterone	Superior rPFS (primary endpoint) Median rPFS: 16.6 vs 10.9 mo (HR 0.53, 95% CI 0.36-0.79)

Anticancer therapy

Niraparib and abiraterone (Akeega) 200/1000 mg PO once per day

Supportive therapy

Prednisone (Sterapred) 5 mg PO twice per day

Continued indefinitely

References

MAGNITUDE: Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. Epub 2023 Mar 23. link to original article link to PMC article PubMed NCT03748641
1. Update: Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, Castro E, Roubaud G, Pereira de Santana Gomes AJ, Small EJ, Rathkopf DE, Gurney H, Jung W, Mason GE, Dibaj S, Wu D, Diorio B, Urtishak K, Del Corral A, Francis P, Kim W, Efstathiou E. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023 Sep;34(9):772-782. Epub 2023 Jul 1. link to original article link to PMC article PubMed

Docetaxel & Prednisone

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Fizazi et al. 2023 (TRITON3)	2017-02-08 to 2022-02-02	Phase 3 (C)	Rucaparib	Inferior PFSi (primary endpoint)

Chemotherapy

Docetaxel (Taxotere) 75 mg/m² IV once on day 1

Endocrine therapy

Prednisone (Sterapred) 5 mg PO twice per day on days 1 to 21

21-day cycle for up to 10 cycles

References

TRITON3: Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. link to original article link to PMC article dosing details in supplement have been reviewed by our editors PubMed NCT02975934

Docetaxel & Prednisolone

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Fizazi et al. 2023 (TRITON3)	2017-02-08 to 2022-02-02	Phase 3 (C)	Rucaparib	Inferior PFSi (primary endpoint)

Chemotherapy

Docetaxel (Taxotere) 75 mg/m² IV once on day 1

Endocrine therapy

Prednisolone (Millipred) 5 mg PO twice per day on days 1 to 21

21-day cycle for up to 10 cycles

References

TRITON3: Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. link to original article link to PMC article dosing details in supplement have been reviewed by our editors PubMed NCT02975934

Enzalutamide monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Fizazi et al. 2023 (TRITON3)	2017-02-08 to 2022-02-02	Phase 3 (C)	Rucaparib	Inferior PFSi (primary endpoint)
de Bono et al. 2020 (PROfound)	2017-04 to 2018-11	Phase 3 (C)	Olaparib	Seems to have inferior OS

Endocrine therapy

Enzalutamide (Xtandi) 160 mg PO once per day

Continued indefinitely

References

PROfound: de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. link to original article dosing details in manuscript have been reviewed by our editors link to supplementary appendix PubMed NCT02987543
1. Update: Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10;383(24):2345-2357. Epub 2020 Sep 20. link to original article PubMed
2. HRQoL analysis: Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Mar;23(3):393-405. Epub 2022 Feb 11. Erratum in: Lancet Oncol. 2022 Apr;23(4):e161. link to original article PubMed
TRITON3: Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. link to original article link to PMC article dosing details in supplement have been reviewed by our editors PubMed NCT02975934

Olaparib monotherapy

Regimen variant #1, 300 mg twice per day

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
de Bono et al. 2020 (PROfound)	2017-04 to 2018-11	Phase 3 (E-RT-switch-ooc)	Physician's choice of: 1a. Abiraterone 1b. Enzalutamide	Superior rPFS (primary endpoint) Median rPFS: 7.4 vs 3.6 mo (HR 0.34, 95% CI 0.25-0.47) Seems to have superior OS¹ (secondary endpoint) Median OS: 19.1 vs 14.7 mo (HR 0.69, 95% CI 0.50-0.97)

¹Reported efficacy is for patients in Cohort A in the 2020 update.

Prior treatment criteria

Progression on abiraterone or enzalutamide

Biomarker eligibility criteria

Cohort A: 1+ alterations in BRCA1, BRCA2, or ATM
Cohort B: 1+ alterations in BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L

Targeted therapy

Olaparib (Lynparza) 300 mg PO twice per day

Continued indefinitely

Regimen variant #2, 400 mg twice per day

Study	Dates of enrollment	Evidence
Kaufman et al. 2014 (Study 42)	2010-02-21 to 2012-07-31	Phase 2, fewer than 20 pts in subgroup
Mateo et al. 2015 (TOPARP-A)	2012-07 to 2014-09	Phase 2

Biomarker eligibility criteria

Study 42: Germline BRCA1/2 mutations and had progression on hormonal and one systemic therapy
TOPARP-A: Patients who were found to have homozygous deletions, deleterious mutations, or both in DNA-repair genes were much more likely to respond to olaparib

Targeted therapy

Olaparib (Lynparza) 400 mg PO twice per day

Continued indefinitely

References

Study 42: Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01078662
TOPARP-A: Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015 Oct 29;373(18):1697-708. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01682772
PROfound: de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. link to original article dosing details in manuscript have been reviewed by our editors link to supplementary appendix PubMed NCT02987543
1. Update: Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10;383(24):2345-2357. Epub 2020 Sep 20. link to original article PubMed
2. HRQoL analysis: Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Mar;23(3):393-405. Epub 2022 Feb 11. Erratum in: Lancet Oncol. 2022 Apr;23(4):e161. link to original article PubMed

Rucaparib monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Abida et al. 2020 (TRITON2)	2017 to not reported	Phase 2 (RT)
Fizazi et al. 2023 (TRITON3)	2017-02-08 to 2022-02-02	Phase 3 (E-switch-ooc)	Physician's choice of: 1a. Abiraterone 1b. Enzalutamide 1c. Docetaxel & Prednisone 1d. Docetaxel & Prednisolone	Superior PFSi (primary endpoint) Median PFSi: 10.2 vs 6.4 mo (HR 0.61, 95% CI 0.47-0.80)

Prior treatment criteria

TRITON3: Progression after treatment with a second-generation androgen-receptor pathway inhibitor

Biomarker eligibility criteria

TRITON3: 1+ alterations in BRCA1, BRCA2, or ATM

Targeted therapy

Rucaparib (Rubraca) 600 mg PO twice per day on days 1 to 28

28-day cycles

References

TRITON2: Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S; TRITON2 investigators. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 Nov 10;38(32):3763-3772. Epub 2020 Aug 14. link to original article dosing details in abstract have been reviewed by our editors link to PMC article PubMed NCT02952534
TRITON3: Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02975934

@@ Line 9: / Line 9: @@
 <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 |}
-<big>'''Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the [[Prostate cancer|main prostate cancer]] page for other regimens.'''</big>
+'''Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the [[Prostate cancer|main prostate cancer]] page for other regimens.'''
 {{TOC limit|limit=3}}
 =Guidelines=
 '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
-==[https://www.nccn.org/ NCCN]==
+==NCCN==
-*''NCCN does not currently have guidelines at this granular level; please see [http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf NCCN Guidelines - Prostate Cancer].''
+*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459 NCCN Guidelines - Prostate Cancer].''
 =Metastatic castration-resistant=
 ==Abiraterone monotherapy {{#subobject:deikoc|Regimen=1}}==
@@ Line 38: / Line 39: @@
 | style="background-color:#fc8d59" |Seems to have inferior OS
 |-
-|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10431499/ Chi et al. 2023 (MAGNITUDE)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10431499/ Chi et al. 2023 (MAGNITUDE)]
 |2019-05 to 2021-03
 | style="background-color:#1a9851" |Phase 3 (C)
@@ Line 53: / Line 54: @@
 </div></div>
 ===References===
-#'''PROfound:''' de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. [http://doi.org/10.1056/NEJMoa1911440 link to original article] '''contains dosing details in manuscript''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_appendix.pdf link to supplementary appendix] [https://pubmed.ncbi.nlm.nih.gov/32343890/ PubMed] [https://clinicaltrials.gov/study/NCT02987543 NCT02987543]
+#'''PROfound:''' de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. [http://doi.org/10.1056/NEJMoa1911440 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_appendix.pdf link to supplementary appendix] [https://pubmed.ncbi.nlm.nih.gov/32343890/ PubMed] [https://clinicaltrials.gov/study/NCT02987543 NCT02987543]
 ## '''Update:''' Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10;383(24):2345-2357. Epub 2020 Sep 20. [https://doi.org/10.1056/nejmoa2022485 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32955174/ PubMed]
 ## '''HRQoL analysis:''' Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Mar;23(3):393-405. Epub 2022 Feb 11. Erratum in: Lancet Oncol. 2022 Apr;23(4):e161. [https://doi.org/10.1016/S1470-2045(22)00017-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35157830/ PubMed]
-#'''TRITON3:''' Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. [https://doi.org/10.1056/NEJMoa2214676 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/36795891/ PubMed] [https://clinicaltrials.gov/study/NCT02975934 NCT02975934]
+#'''TRITON3:''' Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. [https://doi.org/10.1056/NEJMoa2214676 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ link to PMC article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36795891/ PubMed] [https://clinicaltrials.gov/study/NCT02975934 NCT02975934]
-#'''MAGNITUDE:''' Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. Epub 2023 Mar 23. [https://doi.org/10.1200/jco.22.01649 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10431499/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36952634/ PubMed] [https://clinicaltrials.gov/study/NCT03748641 NCT03748641]
+#'''MAGNITUDE:''' Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. Epub 2023 Mar 23. [https://doi.org/10.1200/jco.22.01649 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10431499/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36952634/ PubMed] [https://clinicaltrials.gov/study/NCT03748641 NCT03748641]
-##'''Update:''' Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, Castro E, Roubaud G, Pereira de Santana Gomes AJ, Small EJ, Rathkopf DE, Gurney H, Jung W, Mason GE, Dibaj S, Wu D, Diorio B, Urtishak K, Del Corral A, Francis P, Kim W, Efstathiou E. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023 Sep;34(9):772-782. Epub 2023 Jul 1. [https://doi.org/10.1016/j.annonc.2023.06.009 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37399894/ PubMed]
+##'''Update:''' Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, Castro E, Roubaud G, Pereira de Santana Gomes AJ, Small EJ, Rathkopf DE, Gurney H, Jung W, Mason GE, Dibaj S, Wu D, Diorio B, Urtishak K, Del Corral A, Francis P, Kim W, Efstathiou E. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023 Sep;34(9):772-782. Epub 2023 Jul 1. [https://doi.org/10.1016/j.annonc.2023.06.009 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849465/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37399894/ PubMed]
 ==Abiraterone & Niraparib {{#subobject:dei9gc|Regimen=1}}==
@@ Line 70: / Line 71: @@
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10431499/ Chi et al. 2023 (MAGNITUDE)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10431499/ Chi et al. 2023 (MAGNITUDE)]
 |2019-05 to 2021-03
 | style="background-color:#1a9851" |Phase 3 (E-RT-esc)
@@ Line 85: / Line 86: @@
 </div></div>
 ===References===
-#'''MAGNITUDE:''' Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. Epub 2023 Mar 23. [https://doi.org/10.1200/jco.22.01649 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10431499/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36952634/ PubMed] [https://clinicaltrials.gov/study/NCT03748641 NCT03748641]
+#'''MAGNITUDE:''' Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. Epub 2023 Mar 23. [https://doi.org/10.1200/jco.22.01649 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10431499/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36952634/ PubMed] [https://clinicaltrials.gov/study/NCT03748641 NCT03748641]
-##'''Update:''' Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, Castro E, Roubaud G, Pereira de Santana Gomes AJ, Small EJ, Rathkopf DE, Gurney H, Jung W, Mason GE, Dibaj S, Wu D, Diorio B, Urtishak K, Del Corral A, Francis P, Kim W, Efstathiou E. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023 Sep;34(9):772-782. Epub 2023 Jul 1. [https://doi.org/10.1016/j.annonc.2023.06.009 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37399894/ PubMed]
+##'''Update:''' Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, Castro E, Roubaud G, Pereira de Santana Gomes AJ, Small EJ, Rathkopf DE, Gurney H, Jung W, Mason GE, Dibaj S, Wu D, Diorio B, Urtishak K, Del Corral A, Francis P, Kim W, Efstathiou E. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023 Sep;34(9):772-782. Epub 2023 Jul 1. [https://doi.org/10.1016/j.annonc.2023.06.009 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849465/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37399894/ PubMed]
+==Docetaxel & Prednisone {{#subobject:8yq3z3 |Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:1c3c28 |Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ Fizazi et al. 2023 (TRITON3)]
+|2017-02-08 to 2022-02-02
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Rucaparib_monotherapy|Rucaparib]]
+| style="background-color:#d73027" |Inferior PFSi (primary endpoint)
+|-
+|}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
+====Endocrine therapy====
+*[[Prednisone (Sterapred)]] 5 mg PO twice per day on days 1 to 21
+'''21-day cycle for up to 10 cycles'''
+</div></div>
+===References===
+#'''TRITON3:''' Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. [https://doi.org/10.1056/NEJMoa2214676 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ link to PMC article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36795891/ PubMed] [https://clinicaltrials.gov/study/NCT02975934 NCT02975934]
+==Docetaxel & Prednisolone {{#subobject:8jfyz3 |Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:agck28 |Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+! style="width: 20%" |Study
+! style="width: 20%" |Dates of enrollment
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |Comparator
+! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ Fizazi et al. 2023 (TRITON3)]
+|2017-02-08 to 2022-02-02
+| style="background-color:#1a9851" |Phase 3 (C)
+|[[#Rucaparib_monotherapy|Rucaparib]]
+| style="background-color:#d73027" |Inferior PFSi (primary endpoint)
+|-
+|}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Chemotherapy====
+*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
+====Endocrine therapy====
+*[[Prednisolone (Millipred)]] 5 mg PO twice per day on days 1 to 21
+'''21-day cycle for up to 10 cycles'''
+</div></div>
+===References===
+#'''TRITON3:''' Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. [https://doi.org/10.1056/NEJMoa2214676 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ link to PMC article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36795891/ PubMed] [https://clinicaltrials.gov/study/NCT02975934 NCT02975934]
 ==Enzalutamide monotherapy {{#subobject:9jgkoc|Regimen=1}}==
 <div class="toccolours" style="background-color:#eeeeee">
@@ Line 117: / Line 170: @@
 </div></div>
 ===References===
-#'''PROfound:''' de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. [http://doi.org/10.1056/NEJMoa1911440 link to original article] '''contains dosing details in manuscript''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_appendix.pdf link to supplementary appendix] [https://pubmed.ncbi.nlm.nih.gov/32343890/ PubMed] [https://clinicaltrials.gov/study/NCT02987543 NCT02987543]
+#'''PROfound:''' de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. [http://doi.org/10.1056/NEJMoa1911440 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_appendix.pdf link to supplementary appendix] [https://pubmed.ncbi.nlm.nih.gov/32343890/ PubMed] [https://clinicaltrials.gov/study/NCT02987543 NCT02987543]
 ## '''Update:''' Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10;383(24):2345-2357. Epub 2020 Sep 20. [https://doi.org/10.1056/nejmoa2022485 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32955174/ PubMed]
 ## '''HRQoL analysis:''' Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Mar;23(3):393-405. Epub 2022 Feb 11. Erratum in: Lancet Oncol. 2022 Apr;23(4):e161. [https://doi.org/10.1016/S1470-2045(22)00017-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35157830/ PubMed]
-#'''TRITON3:''' Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. [https://doi.org/10.1056/NEJMoa2214676 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/36795891/ PubMed] [https://clinicaltrials.gov/study/NCT02975934 NCT02975934]
+#'''TRITON3:''' Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. [https://doi.org/10.1056/NEJMoa2214676 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ link to PMC article] '''dosing details in supplement have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36795891/ PubMed] [https://clinicaltrials.gov/study/NCT02975934 NCT02975934]
 ==Olaparib monotherapy {{#subobject:defe72|Regimen=1}}==
@@ Line 188: / Line 241: @@
 ===References===
 <!-- Presented at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013. -->
-#'''Study 42:''' Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. [https://doi.org/10.1200/jco.2014.56.2728 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6057749/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25366685/ PubMed] [https://clinicaltrials.gov/study/NCT01078662 NCT01078662]
+#'''Study 42:''' Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. [https://doi.org/10.1200/jco.2014.56.2728 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6057749/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25366685/ PubMed] [https://clinicaltrials.gov/study/NCT01078662 NCT01078662]
-#'''TOPARP-A:''' Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015 Oct 29;373(18):1697-708. [https://doi.org/10.1056/NEJMoa1506859 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228595/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26510020/ PubMed] [https://clinicaltrials.gov/study/NCT01682772 NCT01682772]
+#'''TOPARP-A:''' Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015 Oct 29;373(18):1697-708. [https://doi.org/10.1056/NEJMoa1506859 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228595/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26510020/ PubMed] [https://clinicaltrials.gov/study/NCT01682772 NCT01682772]
-#'''PROfound:''' de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. [http://doi.org/10.1056/NEJMoa1911440 link to original article] '''contains dosing details in manuscript''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_appendix.pdf link to supplementary appendix] [https://pubmed.ncbi.nlm.nih.gov/32343890/ PubMed] [https://clinicaltrials.gov/study/NCT02987543 NCT02987543]
+#'''PROfound:''' de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. Epub 2020 Apr 28. [http://doi.org/10.1056/NEJMoa1911440 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_appendix.pdf link to supplementary appendix] [https://pubmed.ncbi.nlm.nih.gov/32343890/ PubMed] [https://clinicaltrials.gov/study/NCT02987543 NCT02987543]
 ## '''Update:''' Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Dec 10;383(24):2345-2357. Epub 2020 Sep 20. [https://doi.org/10.1056/nejmoa2022485 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32955174/ PubMed]
 ## '''HRQoL analysis:''' Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Mar;23(3):393-405. Epub 2022 Feb 11. Erratum in: Lancet Oncol. 2022 Apr;23(4):e161. [https://doi.org/10.1016/S1470-2045(22)00017-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35157830/ PubMed]
@@ Line 204: / Line 257: @@
 ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655021/ Abida et al. 2020 (TRITON2)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655021/ Abida et al. 2020 (TRITON2)]
 <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
 |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-230-1 <span style="color:white;">ESMO-MCBS (3)</span>]'''
 |-
 |} -->
-|2017-NR
+|2017 to not reported
 |style="background-color:#91cf61"|Phase 2 (RT)
 | style="background-color:#d3d3d3" |
@@ Line 233: / Line 286: @@
 </div></div>
 ===References===
-# '''TRITON2:''' Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S; TRITON2 investigators. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 Nov 10;38(32):3763-3772. Epub 2020 Aug 14. [https://doi.org/10.1200/jco.20.01035 link to original article] '''contains dosing details in abstract''' [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655021/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32795228/ PubMed] [https://clinicaltrials.gov/study/NCT02952534 NCT02952534]
+# '''TRITON2:''' Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S; TRITON2 investigators. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 Nov 10;38(32):3763-3772. Epub 2020 Aug 14. [https://doi.org/10.1200/jco.20.01035 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7655021/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32795228/ PubMed] [https://clinicaltrials.gov/study/NCT02952534 NCT02952534]
-#'''TRITON3:''' Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. [https://doi.org/10.1056/NEJMoa2214676 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/36795891/ PubMed] [https://clinicaltrials.gov/study/NCT02975934 NCT02975934]
+#'''TRITON3:''' Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. Epub 2023 Feb 16. [https://doi.org/10.1056/NEJMoa2214676 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064172/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/36795891/ PubMed] [https://clinicaltrials.gov/study/NCT02975934 NCT02975934]
 [[Category:Prostate cancer regimens]]
 [[Category:Biomarker-specific pages]]
-[[Category:Genitourinary cancers]]
+[[Category:Male genital cancers]]

Difference between revisions of "Prostate cancer, BRCA-mutated"

Latest revision as of 17:13, 17 July 2024

Guidelines

NCCN

Metastatic castration-resistant

Abiraterone monotherapy

Regimen

Endocrine therapy

Supportive therapy

References

Abiraterone & Niraparib

Regimen

Anticancer therapy

Supportive therapy

References

Docetaxel & Prednisone

Regimen

Chemotherapy

Endocrine therapy

References

Docetaxel & Prednisolone

Regimen

Chemotherapy

Endocrine therapy

References

Enzalutamide monotherapy

Regimen

Endocrine therapy

References

Olaparib monotherapy

Regimen variant #1, 300 mg twice per day

Prior treatment criteria

Biomarker eligibility criteria

Targeted therapy

Regimen variant #2, 400 mg twice per day

Biomarker eligibility criteria

Targeted therapy

References

Rucaparib monotherapy

Regimen

Prior treatment criteria

Biomarker eligibility criteria

Targeted therapy

References

Navigation menu

Search